<?xml version="1.0" encoding="UTF-8" ?>
<modsCollection xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" xmlns:slims="http://senayan.diknas.go.id" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd">
<mods version="3.3" ID="1615">
<titleInfo>
<title>Marmara Pharmaceutical Journal of Research in Pharmacy Journal of Research in Pharmacy2022 , Vol 26 Issue 1</title>
</titleInfo>
<typeOfResource manuscript="yes" collection="yes">mixed material</typeOfResource>
<genre authority="marcgt">bibliography</genre>
<originInfo>
<place><placeTerm type="text"></placeTerm></place>
<publisher></publisher>
<dateIssued></dateIssued>
<issuance>monographic</issuance>
<edition>2022 , Vol 26 Issue 1</edition>
</originInfo>
<language>
<languageTerm type="code">id</languageTerm>
<languageTerm type="text">Indonesia</languageTerm>
</language>
<physicalDescription>
<form authority="gmd">Karya Tulis Ilmiah</form>
<extent></extent>
</physicalDescription>
<note>ABSTRACT: (R,S)-Etodolac [1,8-diethyl-1,3,4,9-tetrahydrapyrano(3,4-b)indole-1-acetic acid] is a nonsteroidal anti-
inflammatory drug that contains carboxylic acid group with the structure of pyrano[3,4-b]indole. In this study, a series

of novel (R,S)-Etodolac derivatives (3a-l) bearing hydrazide-hydrazone moiety were synthesized. The structures of
these compounds were characterized by spectral (1H-NMR and FT-IR analyses) methods. All synthesized compounds
were screened for anticancer activity against androgen-independent prostate adenocarcinoma (PC-3, DU-145) and
androgen-dependent prostate adenocarcinoma (LNCaP) cell lines by using WST-8 colorimetric method. This method
was used for cell viability and cytotoxicity analysis. Compound 3b (SGK-720) [2-(1,8-diethyl-1,3,4,9-
tetrahydropyrano[3,4-b]indole-1-yl)acetic acid[(2,6-dichlorophenyl)methylene]hydrazides] showed 10.36, 5.24, 15.53
&mu;M anticancer activity against PC3, DU145, LNCaP cancer cell lines, respectively. According to JC-1 mitochondrial
membrane potential test and Annexin V/PI staining, 3b was found to have apoptotic effect on these cancer cells. It is
concluded that compound 3b containing 2,6-dichloro substituents may be one of the candidate molecules to cope with
prostate cancer.
KEYWORDS: Etodolac; hydrazide-hydrazone; anticancer activity; apoptosis; WST-8 colorimetric method.</note>
<classification></classification><identifier type="isbn"></identifier><location>
<physicalLocation>PERPUSTAKAAN SEKOLAH TINGGI ILMU KESEHATAN SAMARINDA REPOSITORY</physicalLocation>
<shelfLocator></shelfLocator>
<holdingSimple>
<copyInformation>
<numerationAndChronology type="1">JIN0079</numerationAndChronology>
<sublocation>Perpus.Akfarsam (jurnal Internasioan)</sublocation>
<shelfLocator>615 MAR b</shelfLocator>
</copyInformation>
</holdingSimple>
</location>
<slims:digitals>
<slims:digital_item id="1690" url="https://drive.google.com/file/d/1oZvqT7pUGQUWimXfRFKaOQi1Sd6N_JSK/view?usp=sharing" path="/https://drive.google.com/file/d/1oZvqT7pUGQUWimXfRFKaOQi1Sd6N_JSK/view?usp=sharing" mimetype="text/uri-list">Marmara Pharmaceutical Journal of Research in Pharmacy Journal of Research in Pharmacy2022 , Vol 26 Issue 1</slims:digital_item>
</slims:digitals><recordInfo>
<recordIdentifier>1615</recordIdentifier>
<recordCreationDate encoding="w3cdtf">2022-07-19 13:24:18</recordCreationDate>
<recordChangeDate encoding="w3cdtf">2022-07-19 13:25:55</recordChangeDate>
<recordOrigin>machine generated</recordOrigin>
</recordInfo></mods></modsCollection>